Cough Syrup Crisis: Indian Pharma Under Fire
Indian authorities have initiated criminal proceedings against Sresan Pharma after a toxic cough syrup, containing high levels of diethylene glycol, led to ten child deaths. The incident intensifies scrutiny on India’s pharmaceutical exports, often dubbed the 'pharmacy of the world', and raises questions about quality control standards.
Authorities in India have taken decisive legal action against Sresan Pharma, a manufacturer of cough syrup, following the tragic deaths of ten children who allegedly consumed contaminated medicine. The syrup was found to contain toxic levels of diethylene glycol, sparking nationwide concern.
India's pharmaceutical industry, already under the microscope for previous incidents in countries like Gambia and Uzbekistan, faces increased scrutiny. Laboratory tests revealed that the syrup, 'Coldrif', had diethylene glycol levels 460 times above the permitted limit, leading to criminal charges against the company and a local doctor, while regulatory measures are imposed.
Sresan Pharma is facing allegations including culpable homicide and drug adulteration. The state's deputy chief minister announced regulatory action and potential license revocation. Other states have also banned the syrup, as India's health ministry advises cautious use of cough syrups in children, emphasizing non-drug treatment for many cough-related illnesses.
(With inputs from agencies.)
Google News